This filing is a routine strategic update without new financial data, guidance, or catalysts. Traders should await the next quarterly or annual filing for concrete evidence of execution against the four-tier strategy. The stock's ultra-micro-cap nature (market cap ~$4M) amplifies volatility on any news, but this release alone does not justify repositioning.
Price Chart
Executive Summary
POMDOCTOR Ltd (POM) filed a 6-K containing a press release that outlines a four-tier diversified revenue strategy (B2C healthcare, AI chronic-disease memberships, B2B enterprise/hospital services, and real-world data offerings). The release repeats FY2025 audited net revenue of ~RMB399.9M (~US$59.04M), previously disclosed in the May 2026 20-F, and provides no new financial guidance, material contracts, or concrete execution milestones. This is a strategic narrative update with no immediately actionable new information.
Key Facts
- Press release describes a four-tier revenue structure: B2C basic healthcare, AI chronic-disease memberships, B2B enterprise/hospital services, and pharmaceutical RWS/RWD services.
- Audited net revenues for FY2025: approximately RMB399.9 million (~US$59.04 million), up from RMB342.6 million in FY2024 (data already public in the 20-F).
- No new financial guidance, share issuance, debt, or material agreements were announced.
- Management commentary is forward-looking and strategy-oriented, with no quantitative targets or timelines.
Financial Impact
No new financial impact disclosed; the FY2025 revenue of ~RMB399.9M was already reported in the annual 20-F filing 81 days prior.
Risk Factors
- Extremely low market cap (~$4M) with history of high volatility and wide bid-ask spreads.
- Forward-looking strategy statements carry no commitment and may not translate to revenue growth or profitability.
- No disclosure of current cash position, burn rate, or near-term funding requirements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-084260 |
| Document: ea0299159-6k_pomdoctor.htm | 0001213900-26-084260 |
| Document: 0001213900-26-084260-index-headers.html | 0001213900-26-084260 |
| Document: 0001213900-26-084260-index.html | 0001213900-26-084260 |
| Document: 0001213900-26-084260.txt | 0001213900-26-084260 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 6-K | $0.5314 $1.13 | ▲ +112.65% | ▲ +112.79% | $1.13 (+112.65%) |
Oct 9, 2026 17d ago | 6-K | $0.6210 $0.5310 | ▲ +14.49% | ▲ +13.00% | $1.13 (−81.96%) |
Sep 30, 2026 26d ago | 6-K | $0.9350 $0.8490 | ▼ −9.20% | ▼ −11.11% | $1.13 (+20.86%) |
Sep 24, 2026 4w ago | 6-K | $0.9700 $0.9200 | ▼ −5.15% | ▼ −4.74% | $1.13 (+16.49%) |
Sep 10, 2026 6w ago | 6-K | $0.7423 $0.8290 | ▲ +11.68% | ▲ +12.18% | $1.13 (+52.23%) |
Aug 27, 2026 8w ago | 6-K | $0.9501 $0.8696 | ▼ −8.47% | ▼ −8.74% | $1.13 (+18.93%) |
Aug 10, 2026 11w ago | 6-K | $1.09 $0.8755 | ▼ −19.68% | ▼ −19.63% | $1.13 (+3.67%) |
Aug 3, 2026 12w ago | 6-K | $0.6880 $1.09 | ▲ +58.43% | ▲ +56.40% | $1.13 (+64.24%) |
Jul 15, 2026 14w ago | 6-K | $1.51 $0.8011 | ▼ −46.95% | ▼ −45.97% | $1.13 (−25.17%) |
Jul 13, 2026 15w ago | 6-K | $1.42 $1.13 | ▼ −20.42% | ▼ −19.64% | $1.13 (−20.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers